The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer

Derek J. Erstad; Andrew M. Tager; Yujin Hoshida; Bryan C. Fuchs

doi:10.1080/23723556.2017.1311827

The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer

Derek J. Erstad, Andrew M. Tager, Yujin Hoshida, Bryan C. Fuchs

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.

Original language	English
Article number	e1311827
Journal	Molecular and Cellular Oncology
Volume	4
Issue number	3
DOIs	https://doi.org/10.1080/23723556.2017.1311827
State	Published - 4 May 2017

Keywords

ATX
HCC
LPA
LPAR1
NASH
chemoprevention
cirrhosis
fibrosis
hepatocellular carcinoma
non-alcoholic steatohepatitis

Access to Document

10.1080/23723556.2017.1311827

Cite this

@article{933dbe66aee84926939efdc65a6d281a,

title = "The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer",

abstract = "Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.",

keywords = "ATX, HCC, LPA, LPAR1, NASH, chemoprevention, cirrhosis, fibrosis, hepatocellular carcinoma, non-alcoholic steatohepatitis",

author = "Erstad, {Derek J.} and Tager, {Andrew M.} and Yujin Hoshida and Fuchs, {Bryan C.}",

note = "Publisher Copyright: {\textcopyright} 2017, {\textcopyright} 2017 The Author(s). Published with license by Taylor & Francis Group, LLC. {\textcopyright} 2017, {\textcopyright} Derek J. Erstad, Andrew M. Tager, Yujin Hoshida, and Bryan C. Fuchs.",

year = "2017",

month = may,

day = "4",

doi = "10.1080/23723556.2017.1311827",

language = "English",

volume = "4",

journal = "Molecular and Cellular Oncology",

issn = "2372-3556",

publisher = "Taylor and Francis Ltd.",

number = "3",

}

TY - JOUR

T1 - The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer

AU - Erstad, Derek J.

AU - Tager, Andrew M.

AU - Hoshida, Yujin

AU - Fuchs, Bryan C.

PY - 2017/5/4

Y1 - 2017/5/4

N2 - Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.

AB - Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.

KW - ATX

KW - HCC

KW - LPA

KW - LPAR1

KW - NASH

KW - chemoprevention

KW - cirrhosis

KW - fibrosis

KW - hepatocellular carcinoma

KW - non-alcoholic steatohepatitis

UR - http://www.scopus.com/inward/record.url?scp=85037622026&partnerID=8YFLogxK

U2 - 10.1080/23723556.2017.1311827

DO - 10.1080/23723556.2017.1311827

M3 - Article

AN - SCOPUS:85037622026

SN - 2372-3556

VL - 4

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

IS - 3

M1 - e1311827

ER -

The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this